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Nonsecretory myeloma (NSM) accounts for\5% of cases of multiple myeloma (MM). The outcome of these
patients following autologous stem cell transplantation (ASCT) has not been evaluated in clinical trials. We
compared the outcomes after ASCT for patients with NSM reported to the Center for International Blood
and Marrow Transplant Research (CIBMTR) between 1989 and 2003, to a matched group of 438 patients (4
controls for each patient) with secretory myeloma (SM). The patients were matched using propensity scores
calculated using age, Durie-Salmon stage, sensitivity to pretransplant therapy, time from diagnosis to trans-
plant, and year of transplant. Disease characteristics were similar in both groups at diagnosis and at transplant
except higher risk of anemia, hypoalbuminemia, and marrow plasmacytosis (in SM) and plasmacytoma (more
in NSM). Cumulative incidence of treatment-related mortality (TRM), relapse, progression-free survival
(PFS), and overall survival (OS) were similar between the groups. In multivariate analysis, based on a Cox
model stratified on matched pairs and adjusted for covariates not considered in the propensity score, we
found no difference in outcome between the NSM and SM groups. In this large cohort of patients undergoing
ASCT, we found no difference in outcomes of patients with NSM compared to those with SM.
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Nonsecretorymultiplemyeloma (NSM), character-
ized by no detectable monoclonal protein in the serum
or urine by conventional techniques, comprises\5%
of all patients with multiple myeloma (MM) [1-7].
The incidence of this condition varies considerably in
different series reflecting referral bias as well as the sen-1134sitivity of laboratory techniques used for thedetectionof
monoclonal protein [4,5,7].Thediagnosis often rests on
the demonstration of monoclonal plasma cell infiltrates
in the marrow as well as presence of lytic bone lesions,
which are common in these patients [1,3]. A cytoplasmic
M-protein can be identified by immunohistochemistry
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true NSM is decreasing [9]. This is especially true
with the introduction of immunoglobulin-free light-
chain assay that is capable of detecting small elevations
in monoclonal-free light chain, which would otherwise
have escaped detection by immunofixation techniques.
PatientswithNSMrepresent a uniqueproblem in terms
of following the response to therapy because of the lack
of a detectablemonoclonal protein in the serumor urine
[3,4,6].No significant differences have been observed in
terms of response to treatment in this group of patients
compared to secretory myeloma (SM), whereas others
have reported better survival in these patients
[3,5,6,10]. Because of the lack of a detectableM-protein,
identification of disease progression tends to be delayed
in this group compared to those with secretory disease.
Autologous stem cell transplantation (ASCT) has been
shown to provide a survival advantage compared to con-
ventional chemotherapy [11,12]. Given the differences
in the clinical characteristics, it is not clear how the re-
sults of ASCT in this group of patients compare with
those with secretory disease. We studied data reported
to the Center for International Blood and Marrow
Transplant Research (CIBMTR), and compared the
outcome of patients with NSM to a matched group of
patients with SM.
PATIENTS AND METHODS
Patients were identified from among those under-
going an ASCT for MM, between 1989 and 2003, re-
ported to the CIBMTR. Patients who were planned
to receive a tandem second ASCT, whether actually
performed or not, were excluded from the current anal-
ysis. CIBMTR datasheets and pathology reports were
reviewed to confirm the diagnosis in nonsecretory pa-
tients. All nonsecretory patients fulfilled the diagnostic
criteria defined as not having a detectable paraprotein
(intact immunoglobulin or light chain) by electropho-
resis/immunofixation electrophoresis in the serum or
urine. A set of patients with secretory disease matched
to the nonsecretory MM patients with respect to sev-
eral clinical features were identified as described below.
A propensity score was used to match pairs for pre-
transplant disease characteristics between the groups
by fitting a logistic regression model. A numeric pro-
pensity score for each nonsecretory MM transplant
was calculated using the variables of age at transplant,
Durie-Salmon stage at diagnosis, sensitivity to pre-
transplant therapy, time from diagnosis to transplant,
and year of transplant. Propensity scores ranged
from 0.02 to 0.127. The aim was to identify 4 matches
for each nonsecretory patient for the matched pair
analysis. NSM transplant recipients (cases) were
matched in random order to SM transplant recipients
(controls) with similar propensity scores. Initially, SM
transplant (case) patients were selected randomly. AnyNS SM transplant (control) patient with a difference in
the propensity score of\0.027 5 (0.127-0.02)/4 was
considered a potential matched control. The matched
control with the smallest difference in propensity score
among all potential matched controls was selected.
These steps were repeated among the remaining cases
until 4 controls were identified for each of the cases.
The primary outcomes studied were treatment-re-
lated mortality (TRM), disease relapse/progression,
progression-free survival (PFS), and overall survival
(OS). Patient-, disease-, and transplant-related variables
for the 2 study groups were compared using the condi-
tional logistic regressionmethod to adjust the matching
pairs. Probabilities of PFS andOSwere calculated using
the Kaplan-Meier estimator; TRM and relapse/pro-
gression were calculated using cumulative incidence es-
timates. The log-rank test was used for univariate
comparisons.MultivariateCox proportional hazards re-
gression model stratified on matched pairs was used to
examine the outcomes between NSM and SM trans-
plantation. The variables listed in Table 1 except those
used in the modeling of the propensity score were
used to build the final model. Any risk factors found to
be significant were adjusted in the finalCoxmodel strat-
ified on matched pairs. All P-values are 2-sided.
RESULTS
The final dataset included 110 NSM HCT recipi-
ents and 438 SM transplant (108 cases were found in
1-4 matches and 2 cases in 1-3 matches), selected
Table 1. Progression-Free Survival Variables Used in the
Propensity Score Calculation for Matching
Nonsecretory Secretory
Variable
n
eval
n
(%)
n
eval
n
(%)
P-
Value
Age at transplant,
years
110 438 .91
<30 1 (1) 2 (<1)
30-39 3 (3) 8 (2)
40-49 28 (26) 114 (26)
50-59 50 (45) 204 (47)
$60 28 (25) 110 (25)
Durie-Salmon stage
at diagnosis
110 438 .48
I 11 (10) 37 (8)
II 24 (22) 97 (22)
III 75 (68) 304 (70)
Sensitivity of myeloma
prior to transplant
110 438 .88
Sensitive 86 (78) 341 (78)
Time from diagnosis
to transplant, months
110 438 .99
<12 85 (77) 332 (76)
$12 25 (23) 106 (24)
Year of transplant 110 438 .34
1989-1992 7 (7) 19 (5)
1993-1996 18 (17) 80 (18)
1997-2000 36 (35) 189 (43)
2001-2003 42 (41) 150 (34)
1136 Biol Blood Marrow Transplant 14:1134-1140, 2008S. Kumar et al.from among 1771 patients reported to the registry dur-
ing this time period, who had the variables available
(total of 2219 patients reported during this time pe-
riod). This yielded the 548 patients in the current anal-
ysis. At the time of the last follow-up, 57 (52%) and
185 (42%) patients were alive in the NSM and SM
group, respectively. The median follow-up of survi-
vors was 61 months for the NSM transplant recipients
and 68 months for the SM transplant recipients.
Baseline Characteristics
The propensity score-basedmatching of cases with
the controls resulted in the 2 groups of patients being
wellmatchedwith respect to the 6 variables used for de-
velopment of the scores as shown in Table 1. The 2
groups were comparable in terms of the baseline
demographics as well as most of the disease character-
istics from the time of diagnosis (Table 2). The NSM
group had a higher proportion of patients with plasma-
cytomas identified at the time of diagnosis (38% versus
10%), and was less anemic (median hemoglobin 13 g/
dL versus 11 g/dL) compared to the SM group. The
groups were otherwise comparable in terms of prog-
nostic factors such as renal function, and serum lactate
dehydrogenase (LDH). The clinical characteristics
were again fairly similar between the 2 groups at the
time of stem cell transplantation (SCT) (Table 3). As
at diagnosis, the SM group had a lower serum albumin
compared to those with NSM. More patients in the
NSM group had received radiotherapy prior to the
transplant, likely a reflection of the higher proportion
of patients presentingwith plasmacytomas.The groups
were well matched in terms of the graft type (marrow
versus peripheral blood), numbers of nucleated cells
collected, and whether any graft purging was per-
formed. The groups were also comparable in terms of
the number and type of chemotherapy regimens they
had received prior to the stem cell transplant.
Outcome after Stem Cell Transplant
Given the potential ambiguity in response assess-
ments in patients with NSM, we focused our outcome
comparisons on PFS and OS. The median PFS from
SCT was 30 months (95% confidence interval [CI],
23-35) among the NSM patients compared to 23
months (95% CI, 19-27) for the SM patients (Plogrank
5 .05) (Figure 1). Similarly, the median OS from
SCT was 62 months (95%CI, 50-68) for the NSM pa-
tients compared to 50 months (95% CI, 42-57) for the
SMpatients (Plogrank5 .26) (Figure 2). ThemedianOS
from diagnosis was similar for the 2 groups; 69 months
(95% CI, 54-76) among the NSM patients compared
to 59 months (95% CI, 53-69) for the SM patients
(Plogrank 5 .34). In a multivariate analysis incorporat-
ing factors not used in the propensity score model,
no differences were seen between the SM and the
NSM group (Table 4).There was no difference in the TRM following
SCT between the 2 groups (Figure 3 and Table 4).
The probability of treatment-related death was 5%
to 8% in both groups. At the time of the analysis,
48% and 58%, in theNSM and the SMgroups, respec-
tively, had died. Relapsed disease was the cause of death
in the majority of patients (75%) in each group, with
infections and organ damage being other common
causes. There were 2 patients who had an allogeneic
stem cell transplant following failed ASCT, and who
had died because of graft-versus-host disease (GVHD).
DISCUSSION
NSM, characterized by the absence of a monoclo-
nal protein in the serum or in the urine, constitutes 1%
Table 2. Baseline Characteristics at Diagnosis of Patients
Who Underwent Autologous Transplantation for Multiple
Myeloma by Secretory Status, Reported to the CIBMTR
between 1989 and 2003
Nonsecretory Secretory
Variable
N
eval
N
(%)
N
eval
N
(%)
P-
Value
Demographics
Number of patients 110 438
Number of centers 58 85
Age, median (range),
years
110 55 (28-74) 438 54 (23-74) .64
Male sex 110 60 (55) 438 264 (60) .25
At Diagnosis
Plasmacytoma at
diagnosis
108 41 (38) 425 41 (10) <.001
Plasma cell (%) in
bone marrow at
diagnosis*
60 43 (0-100) 335 49 (0-100) .04
International Staging
System at diagnosis
45 241 .22
I 24 (54) 99 (41)
II 15 (33) 89 (37)
III 6 (13) 53 (22)
Immunochemical
subtype of myeloma
NA 438 —
IgG 273 (63)
IgA 82 (19)
IgD 6 (1)
Light chain 76 (17)
Not specified 1 (<1)
Hemoglobin at
diagnosis <10 g/dL
95 14 (15) 400 154 (39) <.001
Albumin at
diagnosis < 3.5 g/dL
77 14 (18) 334 137 (41) <.001
Creatinine at diagnosis
>1 mg/dL 82 46 (56) 356 203 (57) .96
>1.5 mg/dL 82 16 (20) 356 96 (27) .11
>2 mg/dL 82 12 (15) 356 62 (17) .49
b2-microglobulin level
at diagnosis $3.5 mg/L
52 16 (31) 256 90 (35) .62
LDH at diagnosis >
upper limit of normal
51 9 (18) 224 39 (17) .65
Serum calcium at
diagnosis >10.5 mg/dL
85 19 (22) 342 70 (20) .79
CIBMTR indicates the Center for International Blood and Marrow
Transplant Research.
*Among patients who did not report extramedullary plasmacytoma at
diagnosis.
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Underwent Autologous Transplantation for Multiple Myeloma
by Immunochemical Subtype, Reported to the CIBMTR
between 1989 and 2003
Nonsecretory Secretory
Variable n eval n (%) n eval n (%) P-Value
Karnofsky score
pretransplant
108 419 .33
<80 11 (10) 49 (12)
80 29 (27) 126 (30)
90-100 68 (63) 244 (58)
Time from
diagnosis to first
chemotherapy, median
(range), months
106 421 .77
<6 97 (92) 388 (92)
6-12 3 (3) 14 (3)
>12 19 (5) 19 (5)
Prior radiotherapy 110 49 (45) 437 134 (31) .005
Prior chemotherapy regimens 109 437 .94
MP ± others 21 (19) 91 (21)
VAD ± others 68 (62) 261 (60)
Cyclophosphamide ±
others
13 (12) 66 (15)
Corticosteroids ± others
(no Cy, no melphalan)
7 (7) 10 (2)
Other 0 8 (2)
None 0 1 (<1)
Number of lines
of chemotherapy*
108 422 .19
0 5 (5) 6 (1)
1 64 (59) 259 (61)
2 31 (29) 104 (25)
>2 8 (7) 53 (13)
Time from
last chemotherapy to
transplant,
median (range), months
107 429 .07
<6 94 (88) 343 (80)
6-12 11 (10) 70 (16)
>12 2 (2) 16 (4)
Disease status
prior to transplant
105 414 .50
Complete/partial
remission
83 (79) 325 (79)
MR/NR/stable disease 18 (17) 67 (16)
Relapse/progressive 4 (4) 22 (5)
Lytic bone
lesions anytime prior
to transplant
102 94 (92) 352 318 (90) .30
LDH prior
to transplant > upper
limit of normal
85 32 (38) 347 115 (33) .70
Albumin prior
to transplant < 3.5 g/dL
94 24 (26) 403 148 (37) .04
b2-microglobulin level
prior to transplant $3.5
mg/L
67 8 (12) 254 51 (20) .10
Total number
of nucleated cells
(108/kg) (PBSC ± BM
only)
80 351 .79
< 2 15 (19) 58 (17)
2-5 22 (27) 89 (25)
>5 43 (54) 204 (58)
Conditioning regimen 110 438 .25
Melphalan only 55 (50) 236 (54)
Melphalan + TBI ± others 8 (7) 61 (14)
Melphalan + others
(not TBI)
25 (23) 44 (10)
TBI ± others
(not melphalan)
4 (4) 21 (5)
(Continued )to 5% of all myeloma, and presents unique diagnostic
and monitoring challenges [1-7]. Randomized trials
have generally tended to exclude patients with NSM
because they do not have easily measurable disease.
In the few trials that did include patients with NSM
(Child et al. [12] 5 4%, Segeren et al. [13] 5 5%,
and Fermand et al. [14] 5 1%), the outcome is not
clearly reported or compared with SM. In the majority
of the patients with NSM, immunoflourescein studies
reveal monoclonal protein in the cytoplasm of the
plasma cells, suggesting defects in secretion or rapid
degradation of the protein as a common mechanism
(‘‘nonsecretors’’) [4,5,8]. Mutations involving the im-
munoglobulin chains can also result in the inability
of cells to secrete the protein [15-17]. Only a small pro-
portion of patients after detailed plasma cell analysis
fail to demonstrate any evidence of immunoglobulin
heavy- or light-chain production [18,19]. With the ad-
vent of more sensitive assays to detect circulating im-
munoglobulin-free light chains, true NSM is
becoming a rarity [9,20,21]. Many of these patients
thought previously to have NSM disease will have de-
tectable abnormalities in the light chain, and may be
appropriately termed hyposecretory disease. In a study
of 28 patients with NSM, 19 were found to have ele-
vated free light chains with abnormal ratios [9]. Several
of the remaining patients had abnormal ratios with
suppression of 1 of the light chains.
Several small patient series have described the pre-
sentation and clinical course of NSM patients. They
tend to be younger by an average of 6 years compared
to those with SM, a feature that cannot be examined in
the current study given the matching characteristics
[3]. As in the current study, these patients tend to
have better hemoglobin levels, with similar levels of
Table 3. (Continued )
Nonsecretory Secretory
Variable n eval n (%) n eval n (%) P-Value
Others† 18 (16) 76 (17)
Graft type 110 438 .27
PBSC 102 (93) 406 (93)
Purging 110 5 (5) 436 29 (7) .41
Total number
of transplants‡
110 438 .32
1 106 (96) 411 (94)
2 or more 4 (4) 27 (6)
Planned post
transplant treatment
109 47 (43) 433 227 (52) .09
Bu indicates busulfan; Cy, cyclophosphamide; MOS, months; PBSC, pe-
ripheral blood stem cells; MR, minimal response; NR, no response;
TBI, total body irradiation; Eval, evaluable.
*Excludes stem cell priming.
†Other conditioning regimens were: Bu + Cy6 others (18 cases in the
nonsecretory group and 67 in the secretory group) and other combina-
tions (9 cases in the secretory group).
‡Patients who had a planned second transplant (whether they received
their second transplant or not) were excluded from the analysis.
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ities such as hypercalcemia [1,3,4,6]. Assessment of re-
sponse to therapy remains a challenge, and often
depends on symptomatic improvement, reduction of
plasmacytomas or bone marrow plasmacytosis, or cor-
rection of anemia and hypercalcemia. Published liter-
ature suggest comparable response rates in these
patients compared with those with SM disease [4].
Other studies have suggested a more favorable out-
come with conventional therapy for NSM [3,6]. Better
outcome in some of these studies may reflect a detec-
tion bias, as these patients may be identified earlier be-
cause of symptoms related to plasmacytomas but could
also be because of differences in the disease biology.
Although recent studies have highlighted potential
molecular mechanisms underlying NSM, data regard-
ing the role of new agents is lacking. Information re-
garding the efficacy of ASCT in patients with NSM
is very limited. Terpos et al. [22] reported improved
PFS in a small sample of 6 NSM patients undergoing
SCT compared to 121 patients with SM.
Given the challenge of detecting disease relapse in
NSM patients, PFS may not represent an ideal end-
point to compare outcomes. In the current study, we
were not able to discern statistically significant im-
provement in PFS (P 5 .05) among patients with
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Figure 1. Demonstrates the PFS following single ASCT in patients with
nonsecretory or SM. No statistically significant difference is seen
between the 2 groups (log-rank test).
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Figure 2. Demonstrates the OS following single ASCT in patients with
nonsecretory or SM. No statistically significant difference is seen
between the 2 groups (log-rank test).NSM. The borderline P-value likely represents the de-
lay in detecting relapse inNSMpatients (where relapse
is defined by marrow plasmacytosis as opposed to bio-
chemical criteria) rather than a true difference in the
time to progression, because there was no difference
in the OS after ASCT between the groups. Although
the reported mortality rate is higher than that seen in
most single institution series or randomized trials, it
was comparable between the groups. These higher
rates likely reflect the effect of a large number of cen-
ters reporting to the registry as well as the long time
period over which the current data was accrued. In
the current study, by selecting a control group of pa-
tients undergoing ASCT in a contemporary period,
balanced for most known prognostic factors, we pro-
vide conclusive evidence in favor of ASCT in patients
with NSM. Clearly, the data presented here is only ap-
plicable to single ASCT for this population because
patients treated on planned tandem ASCT protocols
were excluded from the analysis. This was confirmed
by the small number of patients actually receiving
Table 4. Relative Risks of Relapse, Treatment-Related Mor-
tality, Treatment Failure, and Mortality with Nonsecretory
versus SecretoryMultipleMyeloma afterASCT inMultivariate
Analysis*
Outcome Event Relative Risk (95% CI) P-value
Treatment-related mortality
Nonsecretory 1.00†
Secretory 1.20 (0.45-3.23) .72
Relapse/progression
Nonsecretory 1.00†
Secretory 0.97 (0.68-1.39) .88
Treatment failure
(death or relapse/progression)
Nonsecretory 1.00†
Secretory 1.09 (0.79-1.52) .59
Mortality
Nonsecretory 1.00†
Secretory 1.16 (0.80-1.68) .44
*Multivariate analysis results are based on fitting a Cox model stratified
on matched pairs adjusted for covariates not considered in the propen-
sity score.
†Reference group.
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Figure 3. Demonstrates the cumulative risk of treatment-related mor-
tality following single ASCT in patients with nonsecretory or SM. No
statistically significant difference is seen between the patient groups
(log-rank test).
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sults from tandem ASCT strategies to this population,
given the lack of benefit in the randomized trials for the
subgroup achieving a very good partial remission, a re-
sponse state not assessable in the NSM group [23].
Data regarding measurement of serum free light
chains, if available, would have provided valuable
insight in the current study. Based on other studies,
it is likely that a significant proportion in the current
cohort of NSM patients would have had detectable
serum-free light chains. Whether differences exist in
the outcome between the ‘‘true’’ NSM and those
with detectable free light-chain abnormality by free
light-chain assays is certainly an important question
and should be addressed in the future. This is rele-
vant, because a previous study had suggested that pa-
tients with light-chain myeloma had inferior survival
following ASCT compared to intact immunoglobulin
G (IgG) or A (IgA) myeloma [24]. This could also
reflect a higher prevalence of the unfavorable translo-
cations among patients with elevated free light chains
[25].
In conclusion, this study represents the largest se-
ries reported on the clinical outcome of patients with
NSM. Because most clinical trials in the past tended
to exclude NSM and given the rarity of the condition,
such an analysis is only feasible using registry data. In
the absence of randomized trials including these pa-
tients, these data represents the best evidence support-
ing similar treatment approaches for this group of
patients. With increasing use of the free light-chain
assay, the majority of patients with NSM are expected
to have detectable light-chain abnormalities, thus
making them oligosecretory rather than ‘‘truly nonse-
cretory.’’ Clinical as well as biologic differences be-
tween the groups of secretory, oligosecretory, and
truly nonsecretory subtypes should be the focus of
future studies.
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